Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

Atherosclerosis refers to the process of fibrofatty plaque formation within arterial walls. This
process may lead to a hemodynamically significant narrowing and disruption of arterial flow …

Background Aspirin is the only antiplatelet agent with a Class I recommendation for long-
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …

Aspirin resistance describes a phenomenon where patients receiving aspirin therapy do not
respond favorably to treatment, and is categorized by continued incidence of adverse …

Cardiovascular disease (CVD) is often associated with asthma, and asthma patients have
an increased risk of CVD mortality. Our understanding of the bidirectional risk of CVD and …

Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …

Abstract Purpose of Review Optimal duration of antiplatelet therapy continues to attract
extensive debates and has been progressively adjusted in the setting of advancements in …

Aims This review summarizes the findings of preclinical studies evaluating the pleiotropic
effects of ticagrelor. These include attenuation of ischemia–reperfusion injury (IRI) …

Background Stroke and bleeding are complications after transcatheter aortic valve
replacement (TAVR). A higher incidence of bleeding and stroke has been reported in …

Background There is no clear consensus on whether aspirin offers better outcomes in terms
of secondary cardiovascular disease prevention compared with clopidogrel. Objective The …